P2B001 Shows Good Efficacy, Safety With Early Parkinson’s in Phase 3 Trial

P2B001 Shows Good Efficacy, Safety With Early Parkinson’s in Phase 3 Trial

315077

P2B001 Shows Good Efficacy, Safety With Early Parkinson’s in Phase 3 Trial

A Phase 3 clinical trial assessing P2B001 in people with early Parkinson’s disease met its primary and a key secondary goal, with the investigative therapy showing superior efficacy to either of its two components, the approved medicines pramipexole and rasagiline, its developer, Pharma Two B, announced. Top-line trial data also showed that P2B001 was well tolerated, and it was better at easing daytime sleepiness than the extended release formulation of pramipexole. “We are thrilled with the positive…

You must be logged in to read/download the full post.